BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 34937944)

  • 21. SWI/SNF complex-deficient soft tissue neoplasms: An update.
    Schaefer IM; Hornick JL
    Semin Diagn Pathol; 2021 May; 38(3):222-231. PubMed ID: 32646614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SWI/SNF catalytic subunits' switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells.
    Wu S; Fatkhutdinov N; Fukumoto T; Bitler BG; Park PH; Kossenkov AV; Trizzino M; Tang HY; Zhang L; Gardini A; Speicher DW; Zhang R
    Nat Commun; 2018 Oct; 9(1):4116. PubMed ID: 30297712
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers.
    Cantley J; Ye X; Rousseau E; Januario T; Hamman BD; Rose CM; Cheung TK; Hinkle T; Soto L; Quinn C; Harbin A; Bortolon E; Chen X; Haskell R; Lin E; Yu SF; Del Rosario G; Chan E; Dunlap D; Koeppen H; Martin S; Merchant M; Grimmer M; Broccatelli F; Wang J; Pizzano J; Dragovich PS; Berlin M; Yauch RL
    Nat Commun; 2022 Nov; 13(1):6814. PubMed ID: 36357397
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model.
    Semaan L; Mander N; Cher ML; Chinni SR
    BMC Cancer; 2019 Oct; 19(1):972. PubMed ID: 31638934
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthetic lethality: targeting SMARCA2 ATPase in SMARCA4-deficient tumors - a review of patent literature from 2019-30 June 2023.
    Reichl KD; Lee ECY; Gopalsamy A
    Expert Opin Ther Pat; 2024 Mar; 34(3):159-169. PubMed ID: 38578210
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting the BAF57 SWI/SNF subunit in prostate cancer: a novel platform to control androgen receptor activity.
    Link KA; Balasubramaniam S; Sharma A; Comstock CE; Godoy-Tundidor S; Powers N; Cao KH; Haelens A; Claessens F; Revelo MP; Knudsen KE
    Cancer Res; 2008 Jun; 68(12):4551-8. PubMed ID: 18559499
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRM: the core ATPase subunit of SWI/SNF chromatin-remodelling complex-a tumour suppressor or tumour-promoting factor?
    Jancewicz I; Siedlecki JA; Sarnowski TJ; Sarnowska E
    Epigenetics Chromatin; 2019 Nov; 12(1):68. PubMed ID: 31722744
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer.
    Hirayama Y; Tam T; Jian K; Andersen RJ; Sadar MD
    Mol Oncol; 2020 Oct; 14(10):2455-2470. PubMed ID: 32734688
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oncogenesis caused by loss of the SNF5 tumor suppressor is dependent on activity of BRG1, the ATPase of the SWI/SNF chromatin remodeling complex.
    Wang X; Sansam CG; Thom CS; Metzger D; Evans JA; Nguyen PT; Roberts CW
    Cancer Res; 2009 Oct; 69(20):8094-101. PubMed ID: 19789351
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The SMARCD Family of SWI/SNF Accessory Proteins Is Involved in the Transcriptional Regulation of Androgen Receptor-Driven Genes and Plays a Role in Various Essential Processes of Prostate Cancer.
    Ertl IE; Brettner R; Kronabitter H; Mohr T; Derdak S; Jeitler M; Bilban M; Garstka N; Shariat SF
    Cells; 2022 Dec; 12(1):. PubMed ID: 36611918
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reactivation of the G1 enhancer landscape underlies core circuitry addiction to SWI/SNF.
    Cermakova K; Tao L; Dejmek M; Sala M; Montierth MD; Chan YS; Patel I; Chambers C; Loeza Cabrera M; Hoffman D; Parchem RJ; Wang W; Nencka R; Barbieri E; Hodges HC
    Nucleic Acids Res; 2024 Jan; 52(1):4-21. PubMed ID: 37993417
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies.
    Vangamudi B; Paul TA; Shah PK; Kost-Alimova M; Nottebaum L; Shi X; Zhan Y; Leo E; Mahadeshwar HS; Protopopov A; Futreal A; Tieu TN; Peoples M; Heffernan TP; Marszalek JR; Toniatti C; Petrocchi A; Verhelle D; Owen DR; Draetta G; Jones P; Palmer WS; Sharma S; Andersen JN
    Cancer Res; 2015 Sep; 75(18):3865-3878. PubMed ID: 26139243
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BAF57 governs androgen receptor action and androgen-dependent proliferation through SWI/SNF.
    Link KA; Burd CJ; Williams E; Marshall T; Rosson G; Henry E; Weissman B; Knudsen KE
    Mol Cell Biol; 2005 Mar; 25(6):2200-15. PubMed ID: 15743818
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRG1 knockdown inhibits proliferation through multiple cellular pathways in prostate cancer.
    Giles KA; Gould CM; Achinger-Kawecka J; Page SG; Kafer GR; Rogers S; Luu PL; Cesare AJ; Clark SJ; Taberlay PC
    Clin Epigenetics; 2021 Feb; 13(1):37. PubMed ID: 33596994
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRD9 Is a Critical Regulator of Androgen Receptor Signaling and Prostate Cancer Progression.
    Alpsoy A; Utturkar SM; Carter BC; Dhiman A; Torregrosa-Allen SE; Currie MP; Elzey BD; Dykhuizen EC
    Cancer Res; 2021 Feb; 81(4):820-833. PubMed ID: 33355184
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The SWI/SNF subunit BRG1 affects alternative splicing by changing RNA binding factor interactions with nascent RNA.
    Gañez-Zapater A; Mackowiak SD; Guo Y; Tarbier M; Jordán-Pla A; Friedländer MR; Visa N; Östlund Farrants AK
    Mol Genet Genomics; 2022 Mar; 297(2):463-484. PubMed ID: 35187582
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extracellular matrix-regulated gene expression requires cooperation of SWI/SNF and transcription factors.
    Xu R; Spencer VA; Bissell MJ
    J Biol Chem; 2007 May; 282(20):14992-9. PubMed ID: 17387179
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Construction of the gene regulatory network identifies MYC as a transcriptional regulator of SWI/SNF complex.
    Srikanth S; Ramachandran S; Mohan S S
    Sci Rep; 2020 Jan; 10(1):158. PubMed ID: 31932624
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinicopathological and prognostic significance of SWI/SNF complex subunits in undifferentiated gastric carcinoma.
    Zhang Z; Li Q; Sun S; Li Z; Cui ZG; Zhang M; Liu Q; Zhang Y; Xiong S; Zhang S
    World J Surg Oncol; 2022 Dec; 20(1):383. PubMed ID: 36464671
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function.
    Gui B; Gui F; Takai T; Feng C; Bai X; Fazli L; Dong X; Liu S; Zhang X; Zhang W; Kibel AS; Jia L
    Proc Natl Acad Sci U S A; 2019 Jul; 116(29):14573-14582. PubMed ID: 31266892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.